While many drugmakers are trying to keep a lid on R&Dexpenses, Amgen reported today in its quarterly earnings that its R&D costs increased 26% to $808 million in order to fund late-stage clinical trials. The biotech giant ($AMGN) now has 10 programs in Phase III development, including studies for the cancer drugs ganitumab and AMG 386, according to the firm's website. Report